Immuron (IMRN) vs Phio Pharmaceuticals (PHIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Phio Pharmaceuticals is the larger company by market cap ($7.8 million vs $7.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRN | PHIO |
|---|---|---|
| Share price | $0.8998 | $0.656 |
| Market cap | $7.26M | $7.84M |
| 1-day change | +5.80% | -8.25% |
| YTD return | — | -37.52% |
| 1-year return | — | -41.43% |
| 5-year return | — | -99.56% |
| EPS (TTM) | $-0.34 | $-1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-8.70M |
| 52-week high | $1.99 | $1.88 |
| 52-week low | $0.677 | $0.6395 |
| Distance from 52-week high | -54.78% | -65.11% |
| Analyst consensus | none | none |
| Avg. price target upside | +332.32% | +2034.15% |
| Average volume | 2.06M | 106.09K |
| Shares outstanding | 8.07M | 11.95M |
| Employees | 7 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immuron
IMRN stock →Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Phio Pharmaceuticals
PHIO stock →Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
IMRN vs PHIO FAQ
Which is bigger, Immuron or Phio Pharmaceuticals?
Phio Pharmaceuticals (PHIO) is larger, with a market capitalization of $7.84M compared with $7.26M for Immuron (IMRN).
Are Immuron and Phio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.